Perion Network Ltd (NASDAQ: PERI) jumped up 22.65% to $11.61 on a traded volume of 264k shares after the Company provided the guidance for fourth quarter and fiscal year 2013. The Company expects revenues in the fourth quarter of 2012 to reach a record $21 million. This will bring total non-GAAP revenues for 2012 to $61 million. The Company expects revenue to exceed $110 million for 2013. EBITDA is expected to be at least $26 million for 2013. Non-GAAP net income is expected to be at least $20 million for the year 2013.

Will PERI Move Higher After Today’s Sudden Selling Activities? Don’t Miss The Free Trend Analysis here 

Star Scientific Inc (NASDAQ: STSI) increased 9.86% to $3.02. The Company announced successful results from the Company's ASAP Human Thyroid Study that analyzes the impact of anatabine dietary supplementation on thyroid health. The study is a three-month, five-visit, double-blind, placebo-controlled study of the impact of anatabine dietary supplementation in humans with autoimmune disease of the thyroid. The study was conducted at nine sites and builds upon previous epidemiological and animal experimental studies. 

How Should Investors Trade STSI After The Recent Momentum, Find Out Here

Cell Therapeutics Inc (NASDAQ: CTIC) moved up 8.46% to $1.41 on a traded volume of 160k shares. The 52-week range for the stock is $1.14 and $8.25. The 50-Day Moving Average and 200-Day Moving Average prices is $1.32 and $2.02 respectively.

Get Free Special Trend Analysis On CTIC Here

Peregrine Pharmaceuticals (NASDAQ: PPHM) escalated 11.93% to $2.71 on a traded volume of 984k shares. The Company said flaws in a study of its experimental lung cancer drug bavituximab didn’t extend to the highest treatment dose. An internal review found that discrepancies in a mid-stage study were limited to the placebo and low-dose treatments. 

Get Free Special Trend Analysis On PPHM Here

Venaxis Inc (NASDAQ: APPY) decreased 5.52% to $2.57. The Company has fulfilled the requirements for CE Marking in Europe for APPY1. APPY1 is the Company’s blood-based appendicitis test.  The initial commercialization in Europe is planned to start in the first quarter 2013 in key territories, including the UK, Italy, France, Germany and Benelux countries.  The Company expects to announce agreements with top EU distributors beginning in the first quarter 2013.

Get Free Special Trend Analysis On APPY Here

About Beststocksdaily

Beststocksdaily’s team is engaged in providing valuable and updated news information on U.S. stocks on a regular basis. Beststocksdaily’s instant stock news on Major Gainers, Hot Stocks and various other stocks, guides investors in making the wise stock market investments decision. To Get Instant updates in the inbox, readers are advised to sign up for free at


The assembled information disseminated by is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. does expect that investors will buy and sell securities based on information assembled and presented in PLEASE always do your own due diligence, and consult your financial advisor.



Brain Burr


1419 Westwood Blvd Los Angeles, CA



Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here